무엇이든 질문하거나 검색하세요...
Hot Research Today
Papers from every journal, all in one place. 맞춤 피드를 만들어 보세요.
meta-analysis · n=73,737언급 6회Expert CommentaryTrending on X
8월 4일SiegalCirculation
OACs in AF are linked to a ~26% incidence of clinically relevant extracranial bleeding.
Clinicians should integrate extracranial bleeding risk into OAC decisions for AF; this meta-analysis extends trial data by quantifying baseline factors' contribution to most attributable risk.
MEMedXY Editorial Team
Medical News Publication, MedXY
This large-scale pooled analysis robustly confirms that extracranial bleeding is a common and clinically meaningful complication in AF patients receiving OAC therapy. The differentiation between major and nonmajor bleeding using standardized ISTH criteria lends uniformity and reproducibility to event adjudication. The predominance of gastrointestinal bleeding among major extracranial bleeds aligns with prior clinical observations, underscoring the importance of GI risk assessment and management (e.g., Helicobacter pylori screening, proton pump inhibitors) in anticoagulated patients.
RCT언급 2회Trending on X
8월 5일O’KeefeStanford University
Each 5-point increase in current SAQ-SS was associated with a lower risk of cardiovascular events in conservative (HR 0.93; 95% CI 0.90-0.96) and invasive (HR 0.91; 95% CI 0.86-0.96) cohorts.
Current SAQ-SS most strongly predicts events; extends serial monitoring value for risk stratification in chronic coronary disease.
Meta-Analysis언급 1회Trending on X
8월 4일DandamudiEuropean Heart Journal - Cardiovascular Imaging
Intracardiac echocardiography during AF ablation ± LAAC showed no significant difference in cardiac tamponade risk compared to TEE (RR 0.86; 95% CI 0.44-1.66; p=0.39).
ICE non-inferior and safe versus TEE for AF ablation ± LAAC; extends evidence supporting anesthesia-free guidance in electrophysiology.
meta-analysis · n=39,452언급 2회Trending on X
8월 3일PackHeart
Pharmacological BP lowering cuts CV death and HF hospitalization ~14%, regardless of reduction degree.
BP lowering shows no outcome benefit in HFmrEF/HFpEF; leaves open whether it mediates therapy effects or warrants targeted trials.
cohort · n=1,160언급 9회Trending on X
8월 3일AyestaránCirculation
LV hypertrabeculation in dilated cardiomyopathy is not associated with increased embolic risk.
Hypertrabeculation in DCM was not linked to higher embolic risk; leaves open its prognostic value across genotypes in prospective studies.
DNDr. Nerea Mora
Cardiologist, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC)
The presence of hypertrabeculation did not modify clinical risk in any of the genetic subgroups analyzed, confirming that it does not confer a worse prognosis.
Cohort Study언급 4회Trending on X
8월 5일WangJAMA Cardiology
Both a small (aHR 1.32; 95% CI 1.28-1.37) and a large (aHR 1.38; 95% CI 1.35-1.40) left ventricle were independently associated with elevated all-cause mortality in patients with heart failure.
LV dimension may refine HF mortality risk stratification beyond LVEF; leaves open whether it should guide therapy.
cohort · n=14언급 2회Trending on X
8월 3일WadaCirculation Reports
EV ICD achieves 100% defibrillation success and high one-year safety in Japanese patients.
EV ICD shows acceptable safety in Japanese patients; extends global data but leaves open need for randomized confirmation.
US
DKDr. Kengo Kusano
Head of the Division of Arrhythmia, National Cerebral and Cardiovascular Center
The Aurora EV-ICD system maintains the same size as conventional transvenous ICDs, reduces the risk of complications in the blood vessels as it is placed outside of the blood vessels. It also offers a major advantage in its ability to deliver ATP therapy, which makes it possible to treat life-threatening arrhythmia effectively while avoiding shock therapy. From patients who participated in the clinical trial, the size of the device was well received, and it is expected to bring great benefits to patients who need ICD devices in the future by reducing their burden and preventing a decline in their quality of life.
meta-analysis · n=2,223언급 2회
8월 3일Al-shammariCardio-Oncology
Spironolactone improves LVEF by ~13% vs placebo during cardiotoxic chemotherapy for breast cancer.
May guide cardioprotective drug selection during breast cancer chemotherapy; extends comparative RCT evidence on LVEF preservation.
Cohort Study언급 7회Trending on X
8월 5일KrügerBMJ
Initiating tirzepatide reduced the risk of MACE compared with sitagliptin among people with type 2 diabetes and established atherosclerotic cardiovascular disease (HR 0.68; 95% CI 0.58 to 0.80).
May support MACE reduction with tirzepatide in T2D and ASCVD; hypothesis-generating and leaves open need for RCTs.
Cohort Study언급 1회Trending on X
8월 5일KhanJohns Hopkins University
The PREVENT-CVD equation accurately predicted 10-year cardiovascular disease risk in US adults, demonstrating a C statistic of 0.788 (95% CI 0.786-0.790).
Supports PREVENT use for contemporary US risk estimation; extends validation to large EHR cohorts but leaves adoption open pending trials.
